The bill directs the Secretary of Health and Human Services, acting through the FDA Commissioner, to undertake a set of administrative and information-driven steps intended to make oversight of human cell and tissue products (HCT/Ps) more predictable. It requires the agency to publish educational materials and best practices for interacting with the FDA’s Tissue Reference Group, to make certain inspection and engagement metrics public, to run stakeholder workshops, and to open a public docket for input on regulatory approaches.
The statute also amends existing language in section 3205 of the Food and Drug Omnibus Reform Act of 2022 to refocus agency efforts on generating scientific data for cellular therapies and requires a report to Congress with concrete regulatory recommendations. For manufacturers, tissue establishments, researchers, and compliance officers, the bill signals a push toward greater transparency and potential clarifications — especially around key legal concepts such as “minimal manipulation” and “homologous use.”
At a Glance
What It Does
The bill requires FDA to publish educational materials about the Tissue Reference Group and best practices for obtaining its recommendations; release specified inspection and engagement statistics on a public website; host workshops and educational sessions; open a public docket for comments; amend prior statutory language to emphasize data-generation best practices; and prepare a report with regulatory recommendations.
Who It Affects
Directly affected parties include tissue establishments and HCT/P manufacturers, academic health centers and research consortia that develop or use cellular products, and FDA reviewers who advise on product classification. Indirectly affected groups include clinicians offering HCT/P-based interventions and patients seeking access to those therapies.
Why It Matters
By codifying transparency, stakeholder education, and a structured input process, the bill attempts to reduce regulatory ambiguity that currently drives costly compliance planning and litigation. Clarifying how the agency will approach minimal manipulation and homologous use could change whether many products are regulated under section 361 or as drugs/biologics, affecting development timelines and market access.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The HCT/P Modernization Act directs FDA to use information and process changes to reduce uncertainty about how HCT/Ps will be regulated. Instead of changing statutory safety standards, it focuses on making the agency’s internal advisory process—the Tissue Reference Group—more accessible: the agency must put explanatory materials and “best practices” online so developers and tissue establishments can better prepare submissions and requests for the group’s recommendations.
Transparency is a central tool: FDA must publish, on its public website, data about registrations, inspections, inquiries to the Tissue Reference Group, and average response times. The bill also tasks FDA with outreach—workshops and interactive sessions aimed at industry, academic centers, consortia, research organizations, and patients—to promote regulatory predictability and to surface scientific gaps that could inform future guidance.Procedurally, the law opens a public docket within 60 days for written comments about workshop topics and modernization approaches, specifically inviting input on how to assess “minimal manipulation” and “homologous use.” It also revises prior statutory language to emphasize generating scientific data for stem cell and cellular therapy development.
Finally, FDA must synthesize workshop and docket input and deliver a recommendations report to Congress that explicitly balances regulatory burden, evolving science, access to 361-regulated products, and public health considerations.The bill does not itself change the definitions in current FDA regulations; rather, it creates a documented, time-bound process for re-examining those regulatory questions and for potentially developing new guidance or policy recommendations based on stakeholder input and scientific data.
The Five Things You Need to Know
The bill requires FDA to post, within one year of enactment and then annually for three years, the number of HCT/P establishments that registered on or after January 1, 2019, the number of inspections of those establishments since that date (with a comparison to blood establishment inspections), the number and type of Tissue Reference Group inquiries in the prior year, and average initial and final response times.
Within 60 days of enactment FDA must establish a public docket accepting written comments on workshop approaches and on modernizing regulation, explicitly including input on assessing “minimal manipulation” and “homologous use.”, The bill amends section 3205 of the Food and Drug Omnibus Reform Act of 2022 to focus the agency’s work on best practices for generating scientific data for stem cell and other cellular therapies (broadening the statutory articulation of the data mission).
FDA is required to conduct workshops, interactive sessions, and stakeholder education directed at industry, tissue establishments, academic health centers, biomedical consortia, research organizations, and patients to support regulatory predictability and scientific advancement.
The Secretary must submit a report to Congress by September 30, 2026, summarizing workshop and docket outcomes and making recommendations regarding regulations (including provisions under 21 C.F.R. §§1271.10(a) and 1271.3), taking into account regulatory burden, scientific developments, access to section 361 products, and public health.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Gives the Act its name: “The HCT/P Modernization Act of 2025.” This is ceremonial but important for citation and for linking this statute to administrative actions and reports required elsewhere in the bill.
Definitions for clarity
Defines three key terms used in the Act: (1) “human cell and tissue product” by reference to the existing regulatory definition in 21 C.F.R. §1271.3(d), (2) “Secretary” as HHS Secretary, and (3) “Tissue Reference Group” as the FDA’s advisory group. By anchoring the definition to existing federal regulation, the bill avoids creating parallel statutory definitions that could cause conflict or interpretive confusion.
Website materials about the Tissue Reference Group
Requires FDA, via the Commissioner, to publish educational materials on the public FDA website describing the Tissue Reference Group and listing best practices for obtaining timely, accurate recommendations from that body. Practically, this obligates the agency to standardize what stakeholders should provide to the Group and how requests should be framed, which could reduce incomplete submissions and repetitive back-and-forths.
Public metrics and stakeholder education
Mandates that FDA publish specified metrics (registrations, inspection counts, inquiry numbers, average response times) starting within one year and annually thereafter for three years, and requires targeted outreach and workshops for industry, tissue establishments, academic centers, consortia, research organizations, and patients. These provisions push the agency toward routine transparency and proactive engagement, both of which can influence inspection priorities and compliance planning by making baseline agency activity visible.
Statutory tweak to prior reform act
Amends section 3205 of the Food and Drug Omnibus Reform Act of 2022 to rephrase the agency’s charge toward producing best practices on generating scientific data for stem cell and other cellular therapies. This is a directional change: it narrows the focus from broader “best practices” language to an explicit data-generation mission, which will shape workshop agendas and guidance development.
Public docket and report to Congress
Directs FDA to open a public docket within 60 days for comments on workshop approaches and on modernization topics (notably minimal manipulation and homologous use) and requires a report to Congress by September 30, 2026, summarizing workshop/docket input and offering recommendations that weigh regulatory burden, scientific developments, access to section 361 products, and public health. Those two tools—docket input and a time-bound report—create a record and a deadline for agency recommendations that stakeholders can use to press for concrete guidance or rulemaking.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Tissue establishments and small-scale manufacturers — Gain clearer expectations and published best practices from FDA about submissions to the Tissue Reference Group, which can reduce wasted time and rework when seeking classification advice.
- Academic health centers and research consortia — Get targeted workshops and educational sessions that can help translate current science into regulatory strategy and identify data gaps to support product development.
- Patients and clinicians using HCT/Ps — Potentially benefit from faster regulatory clarity that may preserve access to 361-regulated interventions or clarify pathways to clinical availability while illuminating safety oversight.
Who Bears the Cost
- FDA/HHS — Must allocate staff time and resources to produce website materials, compile and publish metrics, run workshops, manage the public docket, and prepare the congressionally mandated report within set deadlines.
- Manufacturers and tissue establishments — May face short-term increased scrutiny if published inspection metrics fuel policy or enforcement attention; providers could incur compliance costs if the agency tightens interpretations of minimal manipulation or homologous use.
- Developers of novel cellular therapies — If the agency’s recommendations narrow exemptions or reinterpret key definitions, firms may need additional clinical studies or to pursue drug/biologic approvals, increasing development time and expense.
Key Issues
The Core Tension
The central dilemma is straightforward: reduce regulatory ambiguity and speed access to beneficial HCT/Ps, or preserve conservative, evidence-driven oversight to protect public health. Clarifying terms like “minimal manipulation” can make life easier for developers and clinicians but also risks moving products out of lower-burden regulatory pathways into full drug/biologic oversight — a shift that improves safety assurance at the cost of higher development barriers and potential access delays.
The bill uses transparency and process to address regulatory uncertainty, but those tools have limits. Publishing inspection and inquiry metrics may show disparities (for example between blood and tissue establishments) without the contextual risk-adjusted analysis that explains whether higher inspection rates reflect higher risk, different business models, or enforcement priorities.
Stakeholders could read raw metrics as grounds for policy change before FDA has conducted a careful causal analysis.
Deadlines and statutory nudges create pressure for recommendations, but speed can trade off with scientific rigor. The requirement to deliver a report by a fixed date pushes FDA to synthesize workshop and docket input quickly; if the agency lacks sufficient empirical evidence, its recommendations could be procedural (process-oriented) rather than substantive, or they could rely heavily on stakeholder submissions that skew toward well-resourced commercial interests.
Finally, revisiting definitions like minimal manipulation and homologous use can reclassify many products; that reclassification risks disrupting patient access and spurring litigation if businesses face retroactive compliance burdens or uncertain grandfathering rules.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.